Wall Street analysts expect that PTC Therapeutics, Inc. (NASDAQ:PTCT) will report ($0.40) earnings per share (EPS) for the current fiscal quarter, Zacks reports. Three analysts have provided estimates for PTC Therapeutics’ earnings, with the lowest EPS estimate coming in at ($0.78) and the highest estimate coming in at $0.10. PTC Therapeutics posted earnings per share of ($0.46) in the same quarter last year, which indicates a positive year over year growth rate of 13%. The company is expected to issue its next quarterly earnings results on Thursday, February 27th.
On average, analysts expect that PTC Therapeutics will report full-year earnings of ($3.55) per share for the current year, with EPS estimates ranging from ($3.87) to ($2.86). For the next fiscal year, analysts anticipate that the company will post earnings of ($1.53) per share, with EPS estimates ranging from ($1.69) to ($1.36). Zacks Investment Research’s earnings per share calculations are an average based on a survey of sell-side research analysts that cover PTC Therapeutics.
PTC Therapeutics (NASDAQ:PTCT) last posted its quarterly earnings data on Tuesday, October 29th. The biopharmaceutical company reported ($1.06) EPS for the quarter, missing the Thomson Reuters’ consensus estimate of ($0.91) by ($0.15). The firm had revenue of $71.40 million during the quarter, compared to analysts’ expectations of $72.03 million. PTC Therapeutics had a negative net margin of 74.86% and a negative return on equity of 31.92%. The company’s quarterly revenue was up 33.2% on a year-over-year basis. During the same quarter last year, the business posted ($1.06) EPS.
Hedge funds have recently modified their holdings of the company. Sector Gamma AS increased its stake in shares of PTC Therapeutics by 17.8% during the 2nd quarter. Sector Gamma AS now owns 229,498 shares of the biopharmaceutical company’s stock worth $10,327,000 after purchasing an additional 34,755 shares during the last quarter. Aperio Group LLC purchased a new position in PTC Therapeutics in the 2nd quarter valued at approximately $168,000. Emerald Advisers LLC grew its stake in PTC Therapeutics by 29.6% in the 2nd quarter. Emerald Advisers LLC now owns 388,010 shares of the biopharmaceutical company’s stock valued at $17,460,000 after buying an additional 88,579 shares in the last quarter. RMB Capital Management LLC purchased a new position in PTC Therapeutics in the 2nd quarter valued at approximately $1,423,000. Finally, Axon Capital LP grew its stake in PTC Therapeutics by 30.4% in the 2nd quarter. Axon Capital LP now owns 216,200 shares of the biopharmaceutical company’s stock valued at $9,729,000 after buying an additional 50,400 shares in the last quarter. Institutional investors own 94.56% of the company’s stock.
NASDAQ:PTCT traded down $0.91 on Friday, hitting $42.88. The stock had a trading volume of 937,300 shares, compared to its average volume of 741,361. The firm’s fifty day simple moving average is $38.77 and its two-hundred day simple moving average is $41.42. The company has a debt-to-equity ratio of 0.44, a quick ratio of 4.30 and a current ratio of 4.40. PTC Therapeutics has a 1 year low of $27.53 and a 1 year high of $48.81. The stock has a market cap of $2.69 billion, a P/E ratio of -23.30 and a beta of 1.88.
About PTC Therapeutics
PTC Therapeutics, Inc, a biopharmaceutical company, focuses on the discovery, development, and commercialization of medicines for the treatment of rare disorders. The company offers Translarna (ataluren) and Emflaza (deflazacort) for the treatment of nonsense mutation Duchenne muscular dystrophy in ambulatory patients.
Recommended Story: How do candlesticks reflect price movement?
For more information about research offerings from Zacks Investment Research, visit Zacks.com
Receive News & Ratings for PTC Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for PTC Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.